Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 11, 2025 226 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EPCORE FL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New on NCI Websites for July 2019 July 2, 2019 The Caregiver Curve March 15, 2021 ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ February 7, 2019 NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials June 29, 2018 Load more HOT NEWS Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma HGTV Star Hilary Farr Shares Breast Cancer Battle
